Accession Number: | 0001209191-23-026742 |
Date: | 2023-04-29 |
Issuer: | ACADIA PHARMACEUTICALS INC (ACAD) |
Original Submission Date: |
DAVIS STEPHEN
C/O ACADIA PHARMACEUTICALS INC.
12830 EL CAMINO REAL, SUITE 400
SAN DIEGO, CA 92130
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2023-04-29 | M | 15,625 | a | $0.00 | 116,103 | direct | ||
COMMON STOCK | 2023-05-01 | S | 7,806 | d | $21.18 | 108,297 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
RESTRICTED STOCK UNITS | 0.0 | 2023-04-29 | deemed execution date | M | 15,625 (d) | common stock 15,625 | $0.00 | 0 | direct |
ID | footnote |
---|---|
f1 | the sales reported in this form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. |
f2 | each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. |
f3 | the restricted stock units vest in four equal annual installments beginning april 29, 2020. |